Antiviral therapy initiated at 32 weeks when maternal viral load is ≥6 log IU/mL almost completely abrogates transmission. Quantitative HBsAg does not reliably predict high viral load. When maternal viral load is <6 log IU/mL, high vaccine efficacy and zero transmission suggests testing infants is of little value.